Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1

Next Previous
X
Search
Trial Profile

A Phase 1/2 Open-label Study Investigating the Safety, Tolerability and Efficacy of ASP0739 as a Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Known to Express NY-ESO-1

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 13 Aug 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ASP 0739 (Primary) ; Pembrolizumab (Primary)
  • Indications Adenocarcinoma; Carcinoma; Malignant melanoma; Myxoid liposarcoma; Non-small cell lung cancer; Oesophageal cancer; Ovarian cancer; Solid tumours; Squamous cell cancer; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Astellas Pharma Global Development

    • Most Recent Events

    • 06 Aug 2024 Status changed to discontinued as the comprehensive assessment of other studies indicated the lack of significant monotherapy activity.
    • 02 Aug 2023 Status changed from active, no longer recruiting to completed.
    • 03 Apr 2023 Planned End Date changed from 31 Jan 2028 to 31 Jul 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top